FOCUS (Nifedipine GITS's Effect on Central Pressure Assessed by Applanation Tonometry)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 365 participants.

Also called NCT01071122

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 365 participants (enrolled count) (from the registry)
Sponsor
  • Bayer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01071122
Other papers using this trial's data
  • Safety of the Up-titration of Nifedipine GITS and Valsartan or Low-dose Combination in Uncontrolled Hypertension: the FOCUS Study Clinical therapeutics, 2016-04 DOI, PubMed 26996246

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01071122. Randomized; no masking; primary purpose treatment. Start 2010-01 (registry gives no type); primary completion 2012-02 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
FOCUS (Nifedipine GITS's Effect on Central Pressure Assessed by Applanation Tonometry)
Condition
Hypertension
Intervention (Drug)
Nifedipine (Adalat, BAYA1040) and Valsartan
Intervention (Drug)
Nifedipine (Adalat, BAYA1040)
Intervention (Drug)
Valsartan
Lead sponsor
Bayer (class: industry)

Record details

Record id
cardio:ct-nct01071122
Content hash
1f621a44b5c55d254562bd7f2afdccba94037adecc2376336a5e06f2927b1ec8